Category: ICAM

´╗┐However, bortezomib, carfilzomib, and comparable brokers generally lack therapeutic activity against solid tumors

´╗┐However, bortezomib, carfilzomib, and comparable brokers generally lack therapeutic activity against solid tumors. UPS. This rationale has driven an intense wave of preclinical and clinical investigation culminating in 2003 with the approval of the proteasomal inhibitor bortezomib by the US Food and Drug Administration for use in multiple myeloma patients. Another proteasomal inhibitor, carfilzomib, is […]